Regulus Therapeutics (NASDAQ:RGLS) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLSGet Rating) in a research note issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

RGLS has been the subject of a number of other research reports. Canaccord Genuity Group initiated coverage on Regulus Therapeutics in a research report on Tuesday, November 8th. They issued a “buy” rating and a $9.00 price target for the company. Canaccord Genuity Group assumed coverage on Regulus Therapeutics in a research report on Monday, November 7th. They set a “buy” rating and a $9.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.67.

Regulus Therapeutics Stock Up 1.8 %

Shares of RGLS opened at $1.66 on Monday. The business has a 50-day simple moving average of $1.72 and a two-hundred day simple moving average of $2.07. The stock has a market cap of $24.29 million, a price-to-earnings ratio of -0.75 and a beta of 1.63. Regulus Therapeutics has a 52 week low of $1.33 and a 52 week high of $4.20.

Institutional Trading of Regulus Therapeutics

Several institutional investors have recently made changes to their positions in RGLS. Renaissance Technologies LLC boosted its stake in Regulus Therapeutics by 498.2% during the first quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 111,100 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Regulus Therapeutics by 42.9% in the 1st quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 50,518 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Regulus Therapeutics in the third quarter worth approximately $54,000. Commonwealth Equity Services LLC raised its holdings in shares of Regulus Therapeutics by 52.3% in the third quarter. Commonwealth Equity Services LLC now owns 33,500 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 11,500 shares during the period. Finally, BlackRock Inc. raised its holdings in shares of Regulus Therapeutics by 108.5% in the third quarter. BlackRock Inc. now owns 45,614 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 23,738 shares during the period. Hedge funds and other institutional investors own 59.60% of the company’s stock.

About Regulus Therapeutics

(Get Rating)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

Read More

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.